ProPhase Labs stock reports a 29.4 percent revenue decline

Published on 10/01/2026 at 05:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ProPhase Labs stock carries a USD 0.1 million market capitalization as of September 30, 2026. Q2 diluted EPS was minus USD 0.22.

PRPH, US74345W1080, Illustration mit AI erstellt.

ProPhase Labs (ISIN US74345W1080) reported Q2 2026 revenue of USD 1.0 million, down 29.4 percent from the comparable period. The company operates in consumer healthcare, diagnostics and genomics, while its shares trade under PRPH on Nasdaq.

Revenue fell to USD 1.0 million

According to ToAlpha in its August 19, 2026 results summary, Q2 2026 revenue was USD 1.0 million, a 29.4 percent year-over-year decline. Consumer Products accounted for USD 4.3 million of fiscal-year 2025 revenue and fell 35.8 percent in that period.

The comparison points to a smaller revenue base in the latest quarterly period than in the prior-year comparison. The reported figures cover revenue rather than ARR, RPO or backlog, keeping the operating signal focused on sales volume.

Losses remain the central metric

ToAlpha also lists diluted EPS of minus USD 0.22 for Q2 2026, a 119.5 percent year-over-year decline, while gross margin was 22.4 percent and operating margin was minus 261.6 percent. The quarterly net margin reached minus 301.8 percent.

ProPhase Labs describes a diversified healthcare model spanning over-the-counter products, diagnostic testing and personal genomics. MarketBeat identifies the company as a Nasdaq-listed healthcare business and names diagnostics, genomics and consumer healthcare products among its activities.

Stock range shows elevated volatility

ProPhase Labs had a market capitalization of USD 0.1 million as of September 30, 2026. Its 52-week range was USD 0.01 to USD 6.70, a wide spread that places the latest valuation near the lower end of the recorded band.

The latest operating figures and the broad annual range create a clear split between business scale and market volatility. For investors, the Q2 revenue comparison and the negative operating margin are the key measurable indicators for assessing the company.

Nasdaq listing and company data

ProPhase Labs was founded in 1989 and is headquartered in Garden City, New York. Its business combines consumer products with diagnostic services, including molecular testing and personal genomics.